WOONSOCKET, R.I., Feb. 6, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that its approximately 9,000 community pharmacies are accepting TrumpRx discount cards, which offer savings on certain medications for those who are eligible, as determined by the drug manufacturers. ...

CVS Health said on Thursday it would swap out Amgen and Eli Lilly's bone disease treatments for lower-cost alternatives in some of its preferred drug lists, starting April 1. ...

Shares of CVS Health (NYSE: CVS) have been declining recently as a potentially lower-than-expected increase in Medicare Advantage rates has investors worried about companies with exposure to health insurance. For CVS, health insurance is indeed a large part of its business as it owns Aetna, which serves millions of people throughout the country. Is CVS Health stock worth buying right now, on weakness, despite some concerning developments in the healthcare sector, or is it too risky to add it to your portfo ...

WOONSOCKET, R.I., Feb. 5, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced new steps to further help customers expand adoption of lower-cost biosimilar medications. Effective April 1, 2026, CVS Caremark will begin offering osteoporosis biosimilars Ospomyv and Stoboclo, as well as generic teriparatide, Bonsity, and Tymlos on major national commercial template formularies. These medications will replace Prolia and Forteo, giving customers and their members more affordable options with strong clini ...

Key Takeaways CVS Health's Pharmacy & Consumer Wellness segment likely led revenue growth in Q4 2025.CVS Health's revenues were supported by the Rite Aid acquisition and higher prescription volume.CVS Health's growth may have been aided by updated COVID-19 vaccines and a strong branded drug mix.CVS Health (CVS) is scheduled to report fourth-quarter 2025 results on Feb. 10, before the market opens.The company posted adjusted earnings per share (EPS) of $1.60 in the last reported quarter, which surpassed the ...

UnitedHealth Group Inc. (NYSE:UNH), CVS Health Corp. (NYSE:CVS), and Humana Inc. (NYSE:HUM) declined last week, but while investors focused on the Donald Trump administration’s proposed near-zero increase in Medicare Advantage, another major regulatory threat emerged late Thursday that could squeeze the industry’s profits from the other end. Shining A Light On ‘Ghost’ Billions The U.S. Department of Labor (DOL), on Jan. 29, issued a landmark proposed regulation demanding “radical transparency” from Pharma ...

I aim to invest in companies with perfect qualitative attributes, buy them at an attractive price based on fundamentals, and hold them forever. I hope to publish articles covering such companies approximately 3 times per week, with extensive quarterly follow-ups and constant updates.I manage a concentrated portfolio targeted at avoiding losers and maximizing exposure to big winners. This means that often I'll rate great companies at a 'Hold' because their growth opportunity is below my threshold, or their d ...

I aim to invest in companies with perfect qualitative attributes, buy them at an attractive price based on fundamentals, and hold them forever. I hope to publish articles covering such companies approximately 3 times per week, with extensive quarterly follow-ups and constant updates.I manage a concentrated portfolio targeted at avoiding losers and maximizing exposure to big winners. This means that often I'll rate great companies at a 'Hold' because their growth opportunity is below my threshold, or their d ...

Wall Street expects a year-over-year decline in earnings on higher revenues when CVS Health (CVS) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 10. ...

CVS Health Corporation (NYSE:CVS) is one of the best cheap stocks to buy for 2026. On January 27, BofA Securities cut its price target on CVS Health Corporation (NYSE:CVS) stock to $95 from $100 while keeping a Buy rating. This cut, stated BofA, was prompted by a recent proposal from the Centers for Medicare & Medicaid Services (CMS) that fell short of market hopes. CVS Health’s (CVS) Path Forward: Policy Challenges, Analyst Views, and Dividend Stability The CMS proposed new policies for the calendar yea ...